These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2515236)

  • 1. Ovarian hyperstimulation associated with the sole use of leuprolide for ovarian suppression.
    Yeh J; Barbieri RL; Ravnikar VA
    J In Vitro Fert Embryo Transf; 1989 Aug; 6(4):261-3. PubMed ID: 2515236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjunctive leuprolide therapy does not improve cycle fecundity in controlled ovarian hyperstimulation and intrauterine insemination of subfertile women.
    Dodson WC; Walmer DK; Hughes CL; Yancy SE; Haney AF
    Obstet Gynecol; 1991 Aug; 78(2):187-90. PubMed ID: 1906152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
    Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
    Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pregnancy: a risk to initiation of leuprolide acetate during the luteal phase before controlled ovarian hyperstimulation.
    Serafini P; Batzofin J; Kerin J; Marrs R
    Fertil Steril; 1988 Aug; 50(2):371-2. PubMed ID: 3135209
    [No Abstract]   [Full Text] [Related]  

  • 5. The efficacy of a combination administration of gonadotropin-releasing hormone agonist and gonadotropins for controlled ovarian hyperstimulation in IVF program.
    Chang YS; Kim SH; Shin CJ; Kim JG; Moon SY; Lee JY
    Asia Oceania J Obstet Gynaecol; 1990 Dec; 16(4):337-45. PubMed ID: 2129188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of gonadotropin releasing hormone agonists in ovulation induction.
    Dodson WC
    J Reprod Med; 1989 Jan; 34(1 Suppl):76-80. PubMed ID: 2497247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gonadotropin-releasing hormone agonist-induced ovarian hyperstimulation: low-dose side effects in women and monkeys.
    Navot D; Rosenwaks Z; Anderson F; Hodgen GD
    Fertil Steril; 1991 Jun; 55(6):1069-75. PubMed ID: 1828042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
    Hsieh YY; Chang CC; Tsai HD
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study.
    Bahçeci M; Ulug U; Ben-Shlomo I; Erden HF; Akman MA
    J Reprod Med; 2005 Feb; 50(2):84-90. PubMed ID: 15755044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful use of gonadotropin-releasing hormone agonist leuprolide for in vitro fertilization in a patient with polycystic ovarian disease and infertility unresponsive to standard treatment.
    Radwanska E; Rawlins RG; Tummon I; Maclin V; Binor Z; Dmowski WP
    Fertil Steril; 1988 Feb; 49(2):356-9. PubMed ID: 3123281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian stimulation for in vitro fertilization using pure follicle-stimulating hormone with and without gonadotropin-releasing hormone agonist in high-responder patients.
    Edelstein MC; Brzyski RG; Jones GS; Oehninger S; Sieg SM; Muasher SJ
    J In Vitro Fert Embryo Transf; 1990 Jun; 7(3):172-6. PubMed ID: 2116488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
    Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
    J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of gonadotrophin-releasing hormone agonists to trigger ovulation.
    Tay CC
    Hum Fertil (Camb); 2002 Feb; 5(1):G35-7; discussion G38-9, G41-8. PubMed ID: 11939159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotropin-releasing hormone agonist (leuprolide acetate) induced ovarian hyperstimulation syndrome in a woman undergoing intermittent hemodialysis.
    Hampton HL; Whitworth NS; Cowan BD
    Fertil Steril; 1991 Feb; 55(2):429-31. PubMed ID: 1899400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian hyperstimulation in polycystic ovary syndrome during therapy with leuprolide acetate.
    Walmer DK; Haney AF; Dodson WC
    Fertil Steril; 1989 Nov; 52(5):858-9. PubMed ID: 2509254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined treatment with gonadotrophin releasing hormone agonist and gonadotrophins in poor responders to hyperstimulation for in vitro fertilization (IVF): clinical and endocrine results.
    McKenna KM; Foster P; McBain J; Martin M; Johnston WI
    Aust N Z J Obstet Gynaecol; 1989 Nov; 29(4):428-32. PubMed ID: 2517193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of the efficiency of controlled ovarian hyperstimulation in the gonadotropin-releasing hormone agonist-suppression cycle using the initial follicle count during gonadotropin stimulation.
    Huang FJ; Chang SY; Tsai MY; Kung FT; Wu JF; Chang HW
    J Assist Reprod Genet; 2001 Feb; 18(2):91-6. PubMed ID: 11285987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe ovarian hyperstimulation syndrome after combined GnRH-agonist and low-dose human chorionic gonadotropin trigger in a patient with a single kidney.
    Pereira N; Lekovich JP; Kligman I; Rosenwaks Z
    Gynecol Endocrinol; 2017 Aug; 33(8):593-597. PubMed ID: 28440686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation.
    Fluker M; Grifo J; Leader A; Levy M; Meldrum D; Muasher SJ; Rinehart J; Rosenwaks Z; Scott RT; Schoolcraft W; Shapiro DB;
    Fertil Steril; 2001 Jan; 75(1):38-45. PubMed ID: 11163814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.